Wells Fargo
APGE

Wells Fargo’s Apogee Therapeutics APGE Stock Holding History

Wells Fargo’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.09M Buy
45,846
+29,319
+177% +$2.64M ﹤0.01% 2651
2026
Q1 		$1.39M Sell
16,527
-25,972
-61% -$1.89M ﹤0.01% 3543
2025
Q4 		$3.21M Buy
42,499
+20,509
+93% +$1.29M ﹤0.01% 3063
2025
Q3 		$874K Buy
21,990
+5,137
+30% +$196K ﹤0.01% 3907
2025
Q2 		$732K Sell
16,853
-1,251
-7% -$47.6K ﹤0.01% 3892
2025
Q1 		$676K Buy
18,104
+399
+2% +$15.4K ﹤0.01% 3883
2024
Q4 		$802K Sell
17,705
-80,585
-82% -$4.11M ﹤0.01% 3866
2024
Q3 		$5.77M Buy
98,290
+86,710
+749% +$4.15M ﹤0.01% 2243
2024
Q2 		$456K Sell
11,580
-1,848
-14% -$89.7K ﹤0.01% 3970
2024
Q1 		$892K Buy
13,428
+7,570
+129% +$331K ﹤0.01% 3536
2023
Q4 		$164K Buy
5,858
+1,455
+33% +$29.2K ﹤0.01% 4594
2023
Q3 		$93.8K Buy
+4,403
New +$97K ﹤0.01% 4816

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Wells Fargo's APGE Position: Q2 2026 in Review

Wells Fargo increased its Apogee Therapeutics (APGE) stake by 177% in Q2 2026, buying an estimated $2.64M and bringing the position to 45,846 shares worth $6.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2651.

Wells Fargo first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Wells Fargo held 45,846 shares of Apogee Therapeutics worth $6.09M as of Q2 2026.
  • Wells Fargo bought 29,319 Apogee Therapeutics shares in Q2 2026, an estimated $2.64M.
  • Apogee Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #2651 holding.
  • Wells Fargo first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.